Home

news and events

About the Speakers

Benjamin Ebert, MD (HST '99), PhD

Benjamin Ebert is Professor of Medicine at Harvard Medical School, an Institute Member of the Broad Institute, and Leader of the Leukemia Program for the Dana-Farber/Harvard Cancer Center.  As of October 1, 2017, he is the Chair of Medical Oncology at the Dana-Farber Cancer Institute.

Dr. Ebert is President of the American Society for Clinical Investigation and an elected member of the Association of American Physicians.  His awards include a Burroughs Wellcome Career Award, a Leukemia and Lymphoma Society Scholar Award, the Till and McCollough Award from the International Society of Experimental Hematopoiesis, and mentoring and teaching awards from Harvard Medical School.  He serves on the medical or scientific advisory boards of the
Evans Foundation, the MDS Foundation, and the Aplastic Anemia and MDS Foundation.

His research focuses on the genetics, biology, and therapy of myeloid malignancies.  This work has led to the characterization of clonal hematopoiesis as a pre-malignant state for hematologic malignancies, and elucidation of the mechanism of action of lenalidomide and related molecules that induce degradation of specific proteins.

Dr. Ebert received a bachelor's degree from Williams College, a doctorate from Oxford University on a Rhodes Scholarship, and an M.D. from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute.  



 

Emma Fink (MD-PhD candidate)

Emma Fink is an MD/PhD student in the Harvard-MIT HST program. Originally from Rochester, NY, she attended Amherst College as an undergraduate, where she double majored in Biology and Chemistry. For her PhD in the Harvard Biological and Biomedical Sciences program, she worked in Ben Ebert's laboratory on a novel class of drugs that induce proteasomal degradation of target proteins. Specifically, Emma worked to elucidate the mechanism of lenalidomide in myelodysplastic syndrome with del(5q) and generated a lenalidomide-responsive mouse to study the effects of these drugs in vivo. Emma will be defending her PhD and returning to medical school this spring.